Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Pet Cancer Diagnostics? An Untapped Market

Stockhouse Editorial
0 Comments| March 19, 2018

{{labelSign}}  Favorites
{{errorMessage}}

Click to enlarge

In many respects, animal health is an under-served field. Many of the medications used to treat animal health disorders are actually human drugs, developed for human physiology, and compounded drugs that have not been proven safe or effective for animal use. Similarly, diagnostic procedures for use on animals are also under-developed.

This is the underserved market that is currently being targeted by Zomedica Pharmaceuticals Corp. The Company originally started with a focus on veterinary pharmaceuticals and has since expanded its focus.

As Zomedica began advancing its pipeline of pet pharmaceutical products, the Company’s attention was drawn to a parallel gap in animal healthcare: diagnostics. ZOM has chosen to begin its efforts in this area with the development of a pet-specific diagnostic option for the most serious of diseases: cancer.

Since launching Zomedica in May 2015, the company has listed on the TSX Venture Exchange followed by the NYSE American exchange, raised over in non-brokered capital, and achieved a market cap of $223.3 million.

On January 5, 2017, Zomedica announced a research agreement with Celsee Diagnostics, Inc. Celsee is a biotech innovator in the capture and counting of circulating tumor cells, also known as liquid biopsy. On December 21, 2017; the two companies took their relationship to the next level.

A licensing and supply agreement is now in place for Zomedica to develop and market Celsee’s liquid biopsy technology for veterinary application as a cancer diagnostic. Stockhouse recently caught up with ZOM’s Chief Operations Officer and Vice President of Product Development, Stephanie Morley, DVM, and Chief Financial Officer Shameze Rampertab, CPA, CA, to learn about the clinical and economic potential of this technology.


Click to enlarge

Download this episode (right click and save)

Get it on iTunesListen on Google Play Music

FULL DISCLOSURE: Zomedica Pharmaceuticals Corp. is a paid client of Stockhouse Publishing.



{{labelSign}}  Favorites
{{errorMessage}}

Comments

No comments yet. Be first to comment!

Leave a Comment

You must be logged in to be able to post a comment.

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today